# Gilles Nobecourt

> Gilles Nobecourt is a Series C investor at Andera Partners backing Health Care and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners)
- Location: Paris, France
- Total investments: 5
- Last investment: Apr 2018
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/gilles-nobecourt/6/109/210

Gilles Nobecourt is a Series C investor at Andera Partners in Paris focused on Health Care and Biotechnology. Gilles has been a Partner at Edmond de Rothschild Investment Partners since 2002. Prior to this he worked as a consultant dedicated to pharmaceutical and biotechnology companies for Russell Reynolds & Associates. In 1988, Gilles started at Rhône-Poulenc Group as Vice President, Public Affairs. In 1992, he was appointed Vice President,assistant to the Chairman and CEO of Rhône-Poulenc Rorer, the pharmaceutical affiliate of Rhône-Poulenc. He then became a founding member of RPR Gencell, the biotechnology division of Rhône-Poulenc Rorer. Initially General Manager for Europe, he subsequently became deputy General Manager of the Division based in San Francisco until 1999. Before he started at Rhône-Poulenc, he was a Field Officer for the United Nations High Commissioner for Refugees in Africa and Central America, advisor to the French Prime Minister (1984-1986), advisor to the French Minister for Industry and Research (1983), Chief of Staff to the President of Languedoc Roussillon Regional Council (1982) and Social Advisor in the French Senate (1981-1982). Gilles graduated from the Paris Institute for Political Sciences (‘Sciences Po Paris’) in 1980, holds also a Master degree in applied economics and a certificate from the Stanford Global School of Business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 60% |
| Biotechnology | 3 | 60% |
| Therapeutics | 2 | 40% |
| Pharmaceutical | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 40% |
| Series B | 1 | 20% |
| Post-IPO Equity | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 1 | 20% |
| United States | 1 | 20% |
| United Kingdom | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Crescendo Biologics | Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies. | $70M | Series B | Apr 30, 2018 |  |
| Complexa | Complexa is a clinical-stage platform biopharmaceutical company researching and developing endogenous human cell signaling technologies targeting an array of prevalent inflammatory, fibrotic, and CNS diseases. The company's proprietary technology involves the synthesis and therapeutic applications of endogenous nitro-fatty acids (NFAs) andadditional structure/function-related mediators that are designed to treat various diseases. NFAs are cell-signaling agents that regulate major inflammatory signaling pathways (e.g., Nrf2, NFkB, and HSF). Capitalizing on their identification and synthesis of these endogenous signaling mediators, Complexa's technologies act to amplify the existing anti-inflammatory and metabolic signaling mechanisms that promote the resolution and repair of acute and chronic tissue injury and disease.It is headquartered in Berwyn, Pennsylvania. | $62M | Series C | Jul 26, 2017 |  |
| Genkyotex | Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases. | $22.7M | Post-IPO Equity | Jan 07, 2015 |  |
| Genkyotex | Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases. | $28.3M | Series C | Jul 09, 2012 |  |
| Genkyotex | Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases. | $20.4M | Series C | May 24, 2011 |  |

5 of 5 investments shown.

## Co-investors
- [Eclosion SA](https://shizune.co/investors/profile/eclosion-sa) — VC Fund, 3 deals together
- [Vesalius Biocapital Partners](https://shizune.co/investors/profile/vesalius-biocapital-partners) — VC Fund, 3 deals together
- [MP Healthcare Venture Management](https://shizune.co/investors/profile/mp-healthcare-venture-management-inc) — VC Fund, 2 deals together
- [Biodiscovery V](https://shizune.co/investors/profile/biodiscovery-v) — VC Fund, 1 deal together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 1 deal together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 1 deal together

## About Andera Partners

VC Fund · Paris, France

Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.

5 contacts available at Andera Partners.

| Name | Title | Profile |
| --- | --- | --- |
| François Boudreault | Censor | https://shizune.co/investors/profile/franois-boudreault |
| Francois Xavier Mauron | Partner | https://shizune.co/investors/profile/francois-xavier-mauron |
| Gilles Nobecourt | Partner | https://shizune.co/investors/profile/gilles-nobecourt |
| Guillem Laporta | Analyst | https://shizune.co/investors/profile/guillem-laporta |
| Jan Van den Bossche | Partner | https://shizune.co/investors/profile/jan-van-den-bossche |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Gilles Nobecourt invest in?

Gilles Nobecourt invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series C and Series B stage. Most of the 5 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gilles Nobecourt last invest?

The most recent investment recorded for Gilles Nobecourt closed in Apr 2018. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co